|
Real-time Estimate
Cboe Europe
04:09:36 2026-09-15 am EDT
|
5-day change | 1st Jan Change | ||
| 1,860.50 GBX | +0.32% |
|
+3.56% | +1.97% |
| 03:52am | GSK plc : Deutsche Bank remains Neutral | ZD |
| 03:35am | GSK Agrees to Buy Potential Blood Cancer Treatment for Up to $750 Million | MT |
| Market Cap | 74.31B 100B 86.8B 81.91B 139B 9,601B 140B 978B 377B 4,870B 376B 368B 15,484B | P/E 2026 * |
14.2x | P/E 2027 * | 11.7x |
|---|---|---|---|---|---|
| Enterprise Value | 95.03B 128B 111B 105B 178B 12,278B 180B 1,251B 482B 6,229B 481B 471B 19,802B | EV / Sales 2026 * |
2.8x | EV / Sales 2027 * | 2.6x |
| Free-Float |
92.75% | Yield 2026 * |
3.75% | Yield 2027 * | 4.04% |
| Markets | Quality | ||
|---|---|---|---|
London S.E.
| GSK | Delayed | |
CBOE
| GSK | Real-time | |
|
OTC Markets
| GLAXF | Delayed | |
|
Xetra
| GS71 | Delayed | |
|
Tradegate
| GS71 | Real-time | |
|
Boerse Muenchen
| GS71 | Real-time | |
|
Mexican S.E.
| GSK1 N | End-of-day quote | |
|
Deutsche Boerse AG
| GS71 | Delayed | |
|
Börse Stuttgart
| GS71 | Delayed |
Last Transcript: GSK plc
| 03:52am | GSK plc : Deutsche Bank remains Neutral | ZD |
| 02:44am | GSK plc : Berenberg gives a Buy rating | ZD |
| Sep. 14 | GSK plc : Gets a Sell rating from JP Morgan | ZD |
| Sep. 14 | GSK plc : JP Morgan reiterates its Sell rating | ZD |
| Sep. 14 | GSK plc : Jefferies keeps its Buy rating | ZD |
| 1 day | +0.34% | ||
| 1 week | +3.56% | ||
| Current month | +0.38% | ||
| 1 month | +0.49% | ||
| 3 months | -4.98% | ||
| 6 months | -8.17% | ||
| Current year | +1.97% |
| 1 week | 1,770 |  | 1,876.68 |
| 1 month | 1,770 | | 1,937 |
| Current year | 1,690 | | 2,282 |
| 1 year | 1,455 | | 2,282 |
| 3 years | 1,242.5 | | 2,282 |
| 5 years | 1,242.5 | | 3,408.16 |
| 10 years | 1,242.5 | | 3,408.16 |
| Manager | Title | Age | Since |
|---|---|---|---|
Luke Miels
CEO | Chief Executive Officer | 52 | 2025-12-31 |
Julie Brown
DFI | Director of Finance/CFO | 64 | 2023-04-30 |
James Ford
CMP | Compliance Officer | - | 2018-07-31 |
| Director | Title | Age | Since |
|---|---|---|---|
Luke Miels
BRD | Director/Board Member | 52 | 2026-05-05 |
Hal Barron
BRD | Director/Board Member | 64 | 2017-12-31 |
Jonathan Symonds
CHM | Chairman | 67 | 2019-08-31 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 9/9/26 | Free | Compliance Officer | 7 | 0.0000% | ||
| 9/9/26 | Buy | Executive/Senior Manager | 7 | 0.0000% | ||
| 9/9/26 | Free | Executive/Senior Manager | 7 | 0.0000% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.32% | +3.56% | +25.79% | +23.24% | 100B | |
| +2.02% | -0.96% | +50.69% | +92.40% | 1,015B | |
| +0.28% | -3.24% | +49.57% | +62.65% | 642B | |
| +1.81% | +2.07% | +19.89% | +70.38% | 463B | |
| -1.09% | +2.11% | +37.44% | +36.94% | 353B | |
| -0.23% | +1.79% | +16.53% | +23.35% | 265B | |
| -0.72% | +1.65% | +5.76% | +10.35% | 254B | |
| +1.10% | -12.75% | +38.03% | +45.44% | 206B | |
| -0.62% | -4.47% | -21.44% | -58.15% | 191B | |
| +1.87% | -3.04% | +27.81% | +89.26% | 182B | |
| Average | +0.38% | -2.93% | +25.01% | +39.59% | 367.04B | |
| Weighted average by Cap. | +0.44% | -2.12% | +33.48% | +55.89% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 33.95B 45.76B 39.65B 37.42B 63.68B 4,386B 64.15B 447B 172B 2,225B 172B 168B 7,074B | 35.49B 47.84B 41.46B 39.12B 66.58B 4,585B 67.06B 467B 180B 2,326B 180B 176B 7,395B |
| Net income | 5.38B 7.25B 6.28B 5.93B 10.09B 695B 10.17B 70.83B 27.29B 353B 27.24B 26.64B 1,121B | 6.37B 8.59B 7.45B 7.03B 11.96B 824B 12.04B 83.91B 32.33B 418B 32.27B 31.56B 1,328B |
| Net Debt | 20.72B 27.93B 24.2B 22.84B 38.87B 2,677B 39.15B 273B 105B 1,358B 105B 103B 4,318B | 17.98B 24.24B 21.01B 19.82B 33.74B 2,324B 33.98B 237B 91.23B 1,179B 91.06B 89.05B 3,748B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-09-15 | GBX 1,861.00 | +0.35% | 364,493 |
| 26-09-14 | GBX 1,854.50 | +4.74% | 4,365,927 |
| 26-09-11 | GBX 1,770.50 | -0.28% | 3,934,440 |
| 26-09-10 | GBX 1,775.50 | -1.55% | 3,018,902 |
| 26-09-09 | GBX 1,803.50 | +0.39% | 3,659,863 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- GSK Stock
Select your edition
All financial news and data tailored to specific country editions
